JP2023541007A - ウイルス感染処置のための化合物および方法 - Google Patents

ウイルス感染処置のための化合物および方法 Download PDF

Info

Publication number
JP2023541007A
JP2023541007A JP2023515155A JP2023515155A JP2023541007A JP 2023541007 A JP2023541007 A JP 2023541007A JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023515155 A JP2023515155 A JP 2023515155A JP 2023541007 A JP2023541007 A JP 2023541007A
Authority
JP
Japan
Prior art keywords
acetylglucosamine
derivative
vitamin
infection
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515155A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022051575A5 (https=
JP2023541007A5 (https=
Inventor
イー ハッサン，アミール
ハサン アフマド ハリーリ，ユーセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassan Ameer E
Khalili Yousef Hasan Ahmad
Original Assignee
Hassan Ameer E
Khalili Yousef Hasan Ahmad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassan Ameer E, Khalili Yousef Hasan Ahmad filed Critical Hassan Ameer E
Publication of JP2023541007A publication Critical patent/JP2023541007A/ja
Publication of JPWO2022051575A5 publication Critical patent/JPWO2022051575A5/ja
Publication of JP2023541007A5 publication Critical patent/JP2023541007A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2023515155A 2020-09-04 2021-09-03 ウイルス感染処置のための化合物および方法 Pending JP2023541007A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074602P 2020-09-04 2020-09-04
US63/074,602 2020-09-04
US202163142669P 2021-01-28 2021-01-28
US63/142,669 2021-01-28
PCT/US2021/048991 WO2022051575A2 (en) 2020-09-04 2021-09-03 Compounds and methods for treating viral infection

Publications (3)

Publication Number Publication Date
JP2023541007A true JP2023541007A (ja) 2023-09-27
JPWO2022051575A5 JPWO2022051575A5 (https=) 2024-09-12
JP2023541007A5 JP2023541007A5 (https=) 2024-09-12

Family

ID=80491477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515155A Pending JP2023541007A (ja) 2020-09-04 2021-09-03 ウイルス感染処置のための化合物および方法

Country Status (7)

Country Link
US (1) US20230346816A1 (https=)
EP (1) EP4208137A4 (https=)
JP (1) JP2023541007A (https=)
CA (1) CA3194024A1 (https=)
MX (1) MX2023002667A (https=)
TW (1) TW202228730A (https=)
WO (1) WO2022051575A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239417A (zh) * 2021-01-29 2022-10-16 艾米爾 Ｅ 哈森 預防病毒感染之方法
CA3256512A1 (en) * 2022-04-21 2023-10-26 Therapeutikos, Inc. METHODS OF TREATING INFLAMMATION
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521299A (ja) * 2003-03-27 2006-09-21 ジョングオ・レンミン・ジイエファンジュン・ディサンジュンイ・ダーシュエ ウイルスまたは細菌の感染により引き起こされる局所病変または全身症状の治療におけるｎ−アセチル−ｄ−グルコサミンの使用
WO2011046057A1 (ja) * 2009-10-15 2011-04-21 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP2012171870A (ja) * 2011-02-17 2012-09-10 Keio Gijuku Ｈｃｖｒｎａ複製抑制剤
JP2014514309A (ja) * 2011-04-15 2014-06-19 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249771A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521299A (ja) * 2003-03-27 2006-09-21 ジョングオ・レンミン・ジイエファンジュン・ディサンジュンイ・ダーシュエ ウイルスまたは細菌の感染により引き起こされる局所病変または全身症状の治療におけるｎ−アセチル−ｄ−グルコサミンの使用
WO2011046057A1 (ja) * 2009-10-15 2011-04-21 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP2012171870A (ja) * 2011-02-17 2012-09-10 Keio Gijuku Ｈｃｖｒｎａ複製抑制剤
JP2014514309A (ja) * 2011-04-15 2014-06-19 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUBCHEM SID:368756742, JPN6025030664, 25 May 2018 (2018-05-25), ISSN: 0005781548 *

Also Published As

Publication number Publication date
MX2023002667A (es) 2023-05-12
WO2022051575A3 (en) 2022-04-07
EP4208137A2 (en) 2023-07-12
WO2022051575A2 (en) 2022-03-10
CA3194024A1 (en) 2022-03-10
EP4208137A4 (en) 2024-08-28
US20230346816A1 (en) 2023-11-02
TW202228730A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
EP3912623B1 (en) Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
US11318138B2 (en) Methods for treating B cell proliferative disorders
JP2023541007A (ja) ウイルス感染処置のための化合物および方法
JP6508785B2 (ja) ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
Rossignol Cryptosporidium and Giardia: treatment options and prospects for new drugs
WO2021195211A1 (en) Quinoline compounds for treating respiratory disorders and viral infections
JP2017521396A (ja) 癌のための併用療法
EP3900717A1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
US10570124B2 (en) Deoxycytidine kinase binding compounds
Su et al. Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents
CA3236069A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
JP2023179435A (ja) 多発性骨髄腫治療
WO2021194991A1 (en) Use of losmapimod for treatment of covid-19
EP4129291A1 (en) Coronavirus infection treatment drug
CN1649874A (zh) 抗寄生虫药青蒿素衍生物(内过氧化物)
JP7511741B2 (ja) ２，３，５－置換されたチオフェン化合物の胃腸管間質腫瘍の予防、改善または治療用途
CN112870206B (zh) 甘露糖在制备预防脑型疟疾药物中的应用
EA034885B1 (ru) Новая схема лечения тиакумициновым соединением
US20220288034A1 (en) Method of reducing aberrant immune response or risk of progression in covid-19
RU2242222C1 (ru) Способ лечения очагового и инфильтративного туберкулеза легких
JP2024505064A (ja) ウイルス感染を予防するための方法
CN120514861B (zh) Nedd8抑制剂在制备抗焦虑药物中的应用
JP2021530512A (ja) 体重増加を抑制するためのロイテリサイクリンまたはラクトバチルス・ロイテリ
JP7654000B2 (ja) テモシリンでの微生物腸内毒素症の管理
CN120695191A (zh) Fr054在逆转胶质母细胞瘤替莫唑胺耐药中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127